SCHEMBL897098

SCHEMBL897098

CC(C)(C(=O)O)c1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
APP P05067 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
OGG1 O15527 1/20 0.39
FPR2 P25090 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MAP4K4 O95819 1/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3497043 0.88 MAPT (0.52) KMT2AMAPTAPPAKR1C3AKR1C2
SCHEMBL9681020 0.84 KMT2A (0.42) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL6673950 0.83 KMT2A (0.41) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL3052505 0.82 KMT2A (0.41) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL27998567 0.82 HDAC1 (0.45) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL7361290 0.82 MEN1 (0.41) KMT2ANPC1RAB9AMEN1CES2
SCHEMBL18982634 0.82 MEN1 (0.41) KMT2ANPC1RAB9AMEN1CES2
SCHEMBL4664901 0.81 SRD5A2 (0.54) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL31058225 0.81 RORC (0.42) KMT2AMAPTNPC1RAB9AMEN1
SCHEMBL1141785 0.80 KMT2A (0.63) KMT2AMAPTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104876853-B The synthetic method of fexofenadine hydrochloride 苏州卫生职业技术学院 2017-06-16 CN claimed
CN-104876853-A Fexofenadine hydrochloride synthesizing method SUZHOU HEALTH COLLEGE 2015-09-02 CN claimed
EP-2532644-A1 Preparation of 2-(4-bromophenyl)-2-methylpropanoic acid Divi's Laboratories Limited (IN) 2012-12-12 EP claimed
US-20120309973-A1 PREPARATION OF 2-(4-BROMOPHENYL)-2-METHYLPROPANOIC ACID DIVI'S LABORATORIES LIMITED (IN) 2012-12-06 US claimed
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
CN-122094688-A Compositions and methods for treating pulmonary arterial hypertension 2026-05-26 CN disclosed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 EP disclosed
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) 2025-12-18 US disclosed
US-12459915-B2 Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2025-11-04 US disclosed
US-20250241908-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) 2025-07-31 US disclosed
CN-119997953-A Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases 上海药苑生物科技有限公司 2025-05-13 CN disclosed
EP-4543443-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) 2025-04-30 EP disclosed
US-20030220375-A1 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives MERCK SHARP & DOHME LLC 2003-11-27 US disclosed
WO-2003066577-A1 N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES WITH A SUBSTIITUENT ON THE METHYL USEFUL AS BRADYKININ ANTAGONISTS MERCK & CO., INC. (US) 2003-08-14 WO disclosed
EP-0117302-B1 PHENOTHIAZINE DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1990-06-27 EP disclosed
CN-87103809-A The method for making of naphthane and indan derivative 1987-12-02 CN disclosed
US-4634699-A ANTIHISTAMINES BURROUGHS WELLCOME CO. (US) 1987-01-06 US disclosed
EP-0117302-A2 Phenothiazine derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1984-09-05 EP disclosed
US-4393233-A FROM ISOBUTYRIC ACID, BROMINE, AND BENZENE ALLIED CORPORATION (US) 1983-07-12 US disclosed
US-4310655-A Polymers of p-(1,1-dimethyl-2-hydroxyethyl)benzoic acid and preparation thereof ALLIED CORPORATION (US) 1982-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309973-A1 PREPARATION OF 2-(4-BROMOPHENYL)-2-METHYLPROPANOIC ACID HRH2, NPFFR2, GABRA6 KMT2A 141/4885MAPT 1798/4885NPC1 4495/4885
US-20030220375-A1 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives BDKRB1, BDKRB2, CNR2 KMT2A 771/4885MAPT 4031/4885NPC1 2432/4885
US-20250241908-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES PHKA1, PHKA2, PHKG1 KMT2A 2582/4885MAPT 1820/4885NPC1 342/4885
US-20250381196-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES PHKA1, PHKA2, PHKG1 KMT2A 2191/4885MAPT 1740/4885NPC1 1064/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT KMT2A 738/4885MAPT 4369/4885NPC1 278/4885
US-12459915-B2 Biaryl derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, LCAT KMT2A 681/4885MAPT 2249/4885NPC1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.